M
Marco Valgimigli
Researcher at University of Bern
Publications - 772
Citations - 91095
Marco Valgimigli is an academic researcher from University of Bern. The author has contributed to research in topics: Percutaneous coronary intervention & Myocardial infarction. The author has an hindex of 105, co-authored 696 publications receiving 69184 citations. Previous affiliations of Marco Valgimigli include University of Düsseldorf & Erasmus University Medical Center.
Papers
More filters
Journal ArticleDOI
Ischemia and Bleeding in Cancer Patients Undergoing Percutaneous Coronary Intervention.
Yasushi Ueki,Benjamin Vögeli,Alexios Karagiannis,Thomas Zanchin,Christian Zanchin,Daniel Rhyner,Tatsuhiko Otsuka,Fabien Praz,George C.M. Siontis,Christina Moro,Stefan Stortecky,Michael Billinger,Marco Valgimigli,Thomas Pilgrim,Stephan Windecker,Thomas M. Suter,Lorenz Räber +16 more
TL;DR: Cancer patients carry an increased risk of cardiac mortality that was not associated with stent-related ischemic events among patients undergoing PCI in routine clinical practice and higher risk of bleeding in cancer patients undergoingPCI deserves particular attention.
Journal ArticleDOI
Perspectives on the 2014 ESC/EACTS Guidelines on Myocardial Revascularization : Fifty Years of Revascularization: Where Are We and Where Are We Heading?
Francesco Costa,Francesco Costa,Sara Ariotti,Sara Ariotti,Marco Valgimigli,Philippe Kolh,Stephan Windecker +6 more
TL;DR: This review aims to highlight the most relevant novelties introduced by the 2014 edition of the ESC/EACTS myocardial revascularization guidelines as compared with the previous edition and to describe similarities and differences with the American societies’ guidelines.
The Significance of Drug–Drug and Drug–Food Interactions of Oral Anticoagulation
TL;DR: It is important to be aware that plasma levels of DOACs are affected by drugs that alter the cell efflux transporter P-glycoprotein and/or cytochrome P450, andDOACs have the potential for pharmacodynamic interaction with antiplatelet agents and non-steroidal anti-inflammatory drugs.
Journal ArticleDOI
Persistence of neointimal growth 12 months after intervention and occurrence of delayed restenosis in patients with left main coronary artery disease treated with drug-eluting stents.
Marco Valgimigli,Patrizia Malagutti,Carlos Van Mieghem,Sophia Vaina,Jurgen Ligthart,George Sianos,Patrick W. Serruys +6 more
TL;DR: Although long-term follow-up after drug-eluting stent (DES) implantation shows a sustained clinical benefit in several registries and randomized trials, little is known about the pattern of neointimal growth beyond the first six to nine months.
Journal ArticleDOI
Impact of Body Mass Index on 5-Year Clinical Outcomes in Patients With ST–Segment Elevation Myocardial Infarction After Everolimus-Eluting or Bare-Metal Stent Implantation
Elisabetta Moscarella,Giosafat Spitaleri,Salvatore Brugaletta,Sara Sentí Farrarons,Alberto Pernigotti,Luis Ortega-Paz,Angel Cequier,Andrés Iñiguez,Antonio Serra,Pilar Jiménez-Quevedo,Vicente Mainar,Gianluca Campo,Maurizio Tespili,Peter den Heijer,Armando Bethencourt,Nicolás Vázquez,Marco Valgimigli,Patrick W. Serruys,Manel Sabaté +18 more
TL;DR: In patients with STEMI who underwent primary PCI, the long-term all-cause death rate decreased as BMI increased, confirming the obesity paradox, irrespective of the stent type.